Abbvie Expands Massachusetts Bioresearch Center with $70 Million Investment

Abbvie is expanding its bioresearch center in Worcester, Massachusetts with a $70 million investment. The expansion will increase biologics manufacturing capacity in the US and enable the transfer of oncology products from Europe to the US. The project is part of Abbvie's $10 billion investment in US biologics manufacturing.

AbbVie Inc. has begun construction on a $70 million expansion of its bioresearch center in Worcester, Massachusetts. The project, part of the company's broader $10 billion investment in U.S. biologics manufacturing, aims to increase the company's manufacturing capacity and expedite the transfer of select oncology products from Europe to the U.S.

The expansion will include the construction of additional biologics manufacturing areas and a three-story building to house laboratory, warehouse, and office space. This investment is a significant milestone in AbbVie's long-term commitment to U.S. manufacturing and supports its mission to develop innovative medicines that address serious health issues.

The expansion is expected to create new jobs at the AbbVie Bioresearch Center (ABC) site and further enhance the company's domestic biologics manufacturing capabilities. With a presence in all 50 states and Puerto Rico, AbbVie employs 28,000 people in the U.S., including more than 2,000 in Massachusetts. This expansion will contribute to the company's goal of supporting over 6,000 American jobs across 11 manufacturing sites.

AbbVie's investment in the U.S. biologics manufacturing sector aligns with the growing global demand for complex biologic medicines, particularly in the areas of immunology and oncology. The company's commitment to innovation and manufacturing capacity expansion underscores its dedication to improving patient outcomes and addressing unmet medical needs.